Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
First Claim
1. A method of alleviating at least one adverse effect of stroke in a patient in need of an increased blood flow to an ischemic region comprising:
- identifying a patient in need of an increased blood flow to an ischemic region, wherein said patient has at least one symptom of stroke; and
providing to said patient an amount of an autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells sufficient to increase blood flow to said ischemic region and alleviate said symptom of stroke wherein said concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells has not been cultured.
9 Assignments
0 Petitions
Accused Products
Abstract
Cells present in adipose tissue are used to stroke and stroke related diseases and disorders in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
196 Citations
15 Claims
-
1. A method of alleviating at least one adverse effect of stroke in a patient in need of an increased blood flow to an ischemic region comprising:
-
identifying a patient in need of an increased blood flow to an ischemic region, wherein said patient has at least one symptom of stroke; and providing to said patient an amount of an autologous, concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells sufficient to increase blood flow to said ischemic region and alleviate said symptom of stroke wherein said concentrated, heterogeneous population of cells comprising adipose-derived stem cells and progenitor cells has not been cultured. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
Specification